An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color
Latest Information Update: 17 Jun 2025
At a glance
- Drugs Lebrikizumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ADmirable
- Sponsors Eli Lilly and Company
Most Recent Events
- 11 Jun 2025 Status changed from active, no longer recruiting to completed.
- 07 Mar 2025 According to an Eli Lilly and Company media release, the company announced that data from this trial will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando.
- 09 Dec 2024 Planned End Date changed from 1 Dec 2024 to 1 Feb 2025.